Emerging roles for novel antipsychotic medications in the treatment of schizophrenia (Q41743497)

8 October 2017

1 reference

title

Emerging roles for novel antipsychotic medications in the treatment of schizophrenia (English)

1 reference

8 October 2017

1 reference

C Andersson

1

1 reference

8 October 2017

M Chakos

series ordinal

2

1 reference

8 October 2017

R Mailman

series ordinal

3

1 reference

8 October 2017

J Lieberman

series ordinal

4

1 reference

8 October 2017

publication date

1 March 1998

1 reference

Psychiatric Clinics of North America

8 October 2017

published in

1 reference

8 October 2017

volume

21

1 reference

8 October 2017

issue

1

1 reference

8 October 2017

page(s)

151-179

1 reference

Neuroleptic-induced akathisia: a review

8 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

A survey of drug-induced extrapyramidal reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. II. Role of neuroleptic treatment, attention, and mental effort

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

The Syndrome of Schizophrenia: Unresolved Questions and Opportunities for Research

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Regional selectivity of neuroleptic drugs: An argument for site specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Negative symptoms: diagnosis, treatment and prognosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Radioreceptor binding profile of the atypical antipsychotic olanzapine.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

The current status of the dopamine hypothesis of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

The selective 5-HT2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse--implications for psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

1 reference

7 January 2021

Deficit and nondeficit forms of schizophrenia: the concept

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Treatment of negative symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Clozapine: neuroleptic-induced EPS and tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Motor and mental aspects of acute extrapyramidal syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

The efficacy of the D2 and 5-HT2 antagonist risperidone (R 64,766) in the treatment of chronic psychosis. An open dose-finding study.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Incidence and correlates of tardive dyskinesia in first episode of schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Sensorimotor and cognitive performance of schizophrenic inpatients treated with haloperidol, flupenthixol, or clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Neuroleptic drug effects on cognitive function in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Prevalence and severity of akathisia in patients on clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Molecular pathology of schizophrenia: more than one disease process?

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

The biology of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Predictors of employment status of treated patients with DSM-III-R diagnosis. Can logistic regression model find a solution?

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Cognitive impairment as a target for pharmacological treatment in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Partial benzodiazepine agonists in schizophrenia: expectations and present clinical findings

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Memory and cognitive function in man: Does the cholinergic system have a specific role?

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Clozapine eligibility among state hospital patients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Testing systems for assessment of negative symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Pilot Clinical Investigation of Risperidone in the Treatment of Psychotic Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

The effect of OPC-4392, a partial dopamine receptor agonist on negative symptoms: results of an open study.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

1 reference

7 January 2021

Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Memory and intelligence in lateralized temporal lobe epilepsy and schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Cognitive deficits in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Prediction of response to phenothiazines in schizophrenia. A crossvalidation study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Prediction of Improvement in Schizophrenia Under Four Phenothiazines

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Performance of schizophrenic patients on putative neuropsychological tests of frontal lobe function.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Further evidence for dementia of the prefrontal type in schizophrenia? A controlled study of teaching the Wisconsin Card Sorting Test.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

What are the functional consequences of neurocognitive deficits in schizophrenia?

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Relations among clinical scales in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Cognitive functioning in chronically hospitalized schizophrenic patients: age-related changes and age disorientation as a predictor of impairment.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

3-PPP, a new centrally acting DA-receptor agonist with selectivity for autoreceptors

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Neuropsychological functioning of first-episode schizophreniform patients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Pharmacological profile of the atypical neuroleptic sertindole

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

The role of excitatory amino acids in neuropsychiatric illness

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Amelioration of negative symptoms in schizophrenia by glycine.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Glycine potentiates the NMDA response in cultured mouse brain neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

[3H]MDL 100,907: a novel selective 5-HT2A receptor ligand

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

The dementia of dementia praecox.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Acute dystonia due to clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Attention and higher cortical functions in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

The effect of neuroleptics on cognitive and psychomotor function

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Schizophrenia with good and poor outcome. I: Early clinical features, response to neuroleptics and signs of organic dysfunction.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Leponex--associated granulocytopenia: a review of the situation

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Memory function in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Negative symptoms as a risk factor for tardive dyskinesia in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Clinical profile of clozapine: adverse reactions and agranulocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

The effects of clozapine on tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

1 reference

7 January 2021

Duration of psychosis and outcome in first-episode schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Risperidone in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Risperidone: clinical development: north American results

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

The pathophysiology of extrapyramidal side-effects of neuroleptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

The deficit state in first-episode schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

An open study of the pharmacokinetics and the tolerability of raclopride extended release capsules in psychiatric patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

The positive-negative distinction in schizophrenia. Review of natural history validators

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Clozapine: is another view valid?

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

The Mechanism of Action of Novel Antipsychotic Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Clozapine's effect on negative symptoms in treatment-refractory schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Predicting rehospitalization at a community mental health center: A „double-crossed” validation

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Assessing cognitive function in schizophrenics and patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol. The International Risperidone Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Psychopharmacologic treatment of negative schizophrenic symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Neuropsychological discriminators of long-term inpatient or outpatient status in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Selective, centrally acting serotonin 5-HT2 antagonists. 1. 2- and 6-substituted 1-phenyl-3-(4-piperidinyl)-1H-indoles

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Negative symptoms in schizophrenia: their longitudinal course and prognostic importance

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Tolerability and therapeutic effect of clozapine. A retrospective investigation of 216 patients treated with clozapine for up to 12 years

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Comparison of pimozide with haloperidol in Gilles de la Tourette syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Update on the clinical efficacy and side effects of clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Seroquel: biochemical profile of a potential atypical antipsychotic.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

The role of 5-HT2A receptors in antipsychotic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Antipsychotic drug doses and neuroleptic/dopamine receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Comparison of short-term administration of sertindole, clozapine and haloperidol on the inactivation of midbrain dopamine neurons in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: acute and repeated treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Race/ethnicity patterns in the homicide of children in Los Angeles, 1980 through 1989

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Seroquel and cognitive improvement in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

The effect of risperidone on cognition in patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

The heterogeneity of memory dysfunction in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Drug-induced dystonia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Pharmacologic properties of (-)-3PPP (preclamol) in man

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Antagonism of phencyclidine-induced hyperactivity by glycine in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

B-HT 920--a novel dopamine autoreceptor agonist in the treatment of patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Neuroleptics and the Natural Course of Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2805%2970365-8

7 January 2021

10.1016/S0193-953X(05)70365-8

Identifiers

DOI

1 reference

8 October 2017

1 reference